Afshinnekoo Ebrahim, Chou Chou, Alexander Noah, Ahsanuddin Sofia, Schuetz Audrey N, Mason Christopher E
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York 10065, USA;; The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, New York, New York 10021, USA;; School of Medicine, New York Medical College, Valhalla, New York 10595, USA.
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York 10065, USA;; The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, New York, New York 10021, USA.
J Biomol Tech. 2017 Apr;28(1):40-45. doi: 10.7171/jbt.17-2801-007. Epub 2017 Mar 21.
Next-generation sequencing (NGS) technologies have ushered in the era of precision medicine, transforming the way we treat cancer patients and diagnose disease. Concomitantly, the advent of these technologies has created a surge of microbiome and metagenomic studies over the last decade, many of which are focused on investigating the host-gene-microbial interactions responsible for the development and spread of infectious diseases, as well as delineating their key role in maintaining health. As we continue to discover more information about the etiology of infectious diseases, the translational potential of metagenomic NGS methods for treatment and rapid diagnosis is becoming abundantly clear. Here, we present a robust protocol for the implementation and application of "precision metagenomics" across various sequencing platforms for clinical samples. Such a pipeline integrates DNA/RNA extraction, library preparation, sequencing, and bioinformatics analyses for taxonomic classification, antimicrobial resistance (AMR) marker screening, and functional analysis (biochemical and metabolic pathway abundance). Moreover, the pipeline has 3 tracks: STAT for results within 24 h; Comprehensive that affords a more in-depth analysis and takes between 5 and 7 d, but offers antimicrobial resistance information; and Targeted, which also requires 5-7 d, but with more sensitive analysis for specific pathogens. Finally, we discuss the challenges that need to be addressed before full integration in the clinical setting.
下一代测序(NGS)技术开创了精准医学时代,改变了我们治疗癌症患者和诊断疾病的方式。与此同时,在过去十年中,这些技术的出现引发了微生物组和宏基因组研究的热潮,其中许多研究专注于调查导致传染病发生和传播的宿主基因-微生物相互作用,以及阐明它们在维持健康方面的关键作用。随着我们不断发现更多关于传染病病因的信息,宏基因组NGS方法在治疗和快速诊断方面的转化潜力变得越来越明显。在这里,我们提出了一个强大的方案,用于在各种测序平台上对临床样本实施和应用“精准宏基因组学”。这样一个流程整合了DNA/RNA提取、文库制备、测序以及用于分类学分类、抗菌药物耐药性(AMR)标记筛选和功能分析(生化和代谢途径丰度)的生物信息学分析。此外,该流程有3条路径:STAT路径可在24小时内出结果;综合路径提供更深入的分析,需要5至7天,但能提供抗菌药物耐药性信息;靶向路径也需要5至7天,但对特定病原体的分析更敏感。最后,我们讨论了在完全整合到临床环境之前需要解决的挑战。